Research on cancer as a disease, from cause to care. Covers tumor biology, small-cell lung cancer, cancer-linked stroke risk, and cancer center research.
Scientists at MUSC Hollings Cancer Center mapped the architecture of healthy breast tissue to uncover early biological changes linked to cancer risk. The study found that body weight and breast density shape the underlying structure of breast tissue, offering new clues about how cancer risk may develop long before tumors form.
Dr. Aditya Bardia has been elected to the American Society for Clinical Investigation for his outstanding contributions to research and patient care in breast cancer treatment. He is advancing precision medicine therapies through antibody-drug conjugates and liquid biopsy technologies.
Researchers found that polyploid cells activate a stress signaling pathway causing increased mobility and engulfing neighboring cells. This behavior can promote tumor growth and therapy resistance in aggressive cancers.
Researchers developed a cancer assessment tool that can identify high-risk patients and specific cell populations linked to their risk. The tool, called scSurvival, predicts survival outcomes more accurately than traditional methods by analyzing single-cell data at cellular resolution.
Colorectal cancer incidence is rising among young individuals in Switzerland, with cancers occurring before age 50 accounting for 6.1% of all cases. The study highlights the importance of awareness and earlier screening to address this trend.
The Alliance for Clinical Trials in Oncology has several active trials specifically designed to help people with head and neck cancers. Trials include testing high-dose prophylactic gabapentin to prevent opioid use during treatment, as well as immunotherapy with nivolumab and cabozantinib for mucosal melanoma and nasopharyngeal carcino...
A new review highlights the role of intestinal stem cells (ISCs) and their supportive microenvironment in driving colorectal cancer initiation, therapy resistance, and relapse. Targeting the ISC–cancer stem cell ecosystem offers a promising strategy to develop next-generation precision care for patients.
Researchers have discovered a way to prevent the collaboration between two important cancer-related proteins, N-MYC and Aurora A. This breakthrough could lead to new medications to combat childhood cancer. The study, published in Nature Communications, provides insights into how these proteins interact with each other.
A Phase II trial found that exercise can improve cognitive function in patients receiving chemotherapy, while low-dose ibuprofen may also have some benefits. The study suggests that exercise is more effective in improving cognitive outcomes, but further research is needed to explore the effects of ibuprofen and combination therapy.
A new study suggests that a low dose of ibuprofen can help alleviate chemo-brain symptoms in cancer patients, but exercise remains the most beneficial intervention. Researchers randomized 86 patients to receive either exercise plus ibuprofen or other treatments and found that exercise significantly improved cognitive function.
A recent study identified distinct microbial signatures in the oral cavity and gut that serve as robust biomarkers for early gastric cancer detection. These microbial markers can be detected in saliva or stool samples using machine learning models, achieving an AUROC of 0.87 for saliva-based detection.
A new study found that cancer types with high lethality receive lower federal research funding, prioritizing these cancers could help direct resources to diseases with greatest potential to reduce suffering. Additionally, certain cancers have a disproportionate impact on underserved populations and quality-of-life burden.
A study by the Alliance Foundation Trials shows that combining immunotherapy and chemotherapy before surgery can help more patients with locally advanced non-small cell lung cancer undergo complete cancer resection, improving their long-term health. The treatment also led to high rates of lymph node clearance and successful surgical re...
Researchers measured mitochondrial function using MRI in 11 cancer survivors, finding slower recovery time signals weaker function, but also a surprising correlation between worse mitochondrial recovery and lower fatigue. The study suggests that subjective experience of fatigue is multidimensional and not solely physical.
Researchers have identified the Prrx1 gene as a key regulator of metastatic potential in breast cancer tumors. This discovery helps explain why highly invasive cells do not always give rise to metastases, and how cells combine invasiveness and proliferation to become the most dangerous from a clinical perspective.
Researchers at St. Jude Children's Research Hospital identified therapy-specific mutations that could guide safer treatments among childhood cancer survivors. The study analyzed genetic mutations in subsequent neoplasms of 160 survivors who developed breast, thyroid malignancies and meningiomas after treatment.
A new MIT study suggests that exposure to NDMA, a chemical contaminant in drinking water and some medications, can cause cancerous mutations more severely in children than adults. The researchers found higher rates of DNA damage and cancer in juvenile mice exposed to low levels of NDMA.
A rare scalp reaction resembling erosive pustular dermatosis was identified in a lung cancer patient treated with amivantamab following cranial radiotherapy. The reaction appeared to be related to impaired wound healing due to dual inhibition of EGFR and MET signaling pathways.
Researchers found that Barrett's oesophagus is the starting point for all cases of oesophageal adenocarcinoma, even when telltale signs are no longer visible. The study suggests that detecting molecular markers such as TFF3 and REG4 could help identify individuals at risk of developing the disease.
Researchers at Ohio State University Wexner Medical Center are refining specialized lymphatic microsurgery techniques to treat and prevent lymphedema. The new procedures, including lymphatic bypass and lymph node transfer, offer patients more options and improved quality of life.
Researchers found that sleep deprivation alters the composition of gut microbiota, leading to worse cancer progression and reduced effectiveness of chemotherapy. The study highlights the importance of maintaining a healthy microbiome through good sleep and diet.
A new study has identified the WWOX protein as a molecular guardian that prevents common skin tumors from undergoing a dangerous metamorphosis and spreading to other parts of the body. The loss of this protein allows cancer cells to transform into more aggressive, invasive forms.
A new study from MIT chemists found that changing the composition of the cell membrane can alter the function of a membrane receptor promoting cell growth. Elevated levels of negatively charged lipids can lock the receptor into an overactive state, contributing to cancer cell proliferation.
A new study led by Dartmouth Cancer Center identifies key barriers to timely head and neck cancer treatment in rural areas, including transportation and caregiver challenges. The research highlights the importance of dedicated staff, strong community ties, and peer support in navigating the complexity of cancer care.
A specific protein, PKC-eta, has been identified as a central driver of aggressive breast cancer cell migration and metastasis. Reducing PKC-eta activity significantly slows tumor growth and reduces metastatic spread in laboratory and animal models.
The Cancer Dependency Map Consortium is launching Phase 3 to expand its research beyond cancer vulnerabilities to investigate resistance and surface targets. The consortium aims to develop novel oncology targets and biomarkers for the next generation of cancer therapies.
Researchers found associations between BRCA1/2 pathogenic variants and four types of cancer: thyroid, bladder, skin, and head and neck. Pathogenic variants in BRCA1 increase thyroid cancer risk, while BRCA2 increases risk for bladder, head and neck, and skin cancers.
A new study reveals that cancer cells may begin escaping therapy much earlier, triggered by a stress response that drives them into a temporary drug-tolerant state. Researchers identified an early molecular trigger: NF-κB, which acts as a regulator of cellular stress and survival.
Research finds PDX1 gene plays a tumor-promoting role in human PCa cells by influencing metabolic pathways. The study identifies PDX1 as differentially hypermethylated in prostate cancer tissues, contributing to its aggressive characteristics.
Researchers developed MitoCatch, a system that targets disease-affected cells with healthy mitochondria. The innovation enables efficient cell type-specific mitochondrial delivery, improving survival of damaged neurons in vitro and retinal ganglion cells in vivo.
The UTHealth Houston-developed dual-payload antibody-drug conjugate technology has been acquired by Eli Lilly, marking a major step towards clinical translation. This technology delivers chemotherapy directly to tumor cells while minimizing damage to healthy tissue, offering a promising approach to cancer treatment.
The study reveals that metabolic dysfunction-associated steatotic liver disease (MASLD) is emerging as a major contributor to liver cancer worldwide and in China. Researchers call for integrated global prevention and early detection strategies to address this growing burden.
The Marlene and Stewart Greenebaum Family Foundation donated $5.5 million to the University of Maryland Greenebaum Comprehensive Cancer Center to fund groundbreaking scientific research and compassionate cancer care. The funds will support innovative treatments, including immunotherapies, and strengthen support for cancer survivors.
The study projects that cancer rates in Canada will be high in 2026, with declines seen in some cancers like colorectal and leukemia. However, death rates from pancreatic cancer are increasing.
Oncology services are often excluded from emergency health priorities, resulting in delayed diagnosis and treatment interruptions. Vulnerable populations, including women and children, face advanced disease stages due to delays in care.
Research from Alberta reveals that survivors of adolescent and young adult cancers are at double the risk of developing most types of later cancers. Lymphoma and breast cancer were found to be the most common subsequent cancers after an initial diagnosis, with breast, colorectal, and lung cancers making up 43% of cases.
A new study maps how rare mixed tumors evolve into hybrid cell states and immune-protected neighborhoods, pointing to new ways to detect and treat combined small-cell lung cancer. The findings reveal that these tumors do not arise from two separate cancers but rather from a single ancestral cell that evolves over time.
A study of over 600,000 people found that early weight gain is associated with a higher risk of dying from various diseases, particularly cardiovascular disease and type 2 diabetes. Weight gain during adulthood also increases the risk of premature death, especially for those who develop obesity at a younger age.
Researchers at ITQB NOVA and IPOLFG are developing a new project called BRIDGE to improve diagnosis and treatment of aggressive breast cancers. They aim to find new biomarkers to monitor cancer evolution and tailor treatment to individual patient needs.
A study by IRB Barcelona researchers sheds light on the regulation of protein production in fatty liver cells, revealing a key role for CPEB4 in controlling gene expression. The findings provide new perspectives on the disease and its progression towards more severe forms.
Several open-source AI models consistently produced summaries that were more comprehensive than physician-written versions, particularly in capturing molecular and genetic findings. The study found that Llama 3.1 and DeepSeek performed best among the six evaluated models.
Nancy L. Lewis, MD, MBS, FACP, a renowned biomedical researcher and clinical trials expert, has been appointed as the new Chief Scientific Officer of the National Comprehensive Cancer Network (NCCN). She will oversee NCCN's programs to advance clinical trials and improve cancer care outcomes globally.
UCLA investigators present new research on targeted drug delivery for colorectal cancer, COVID-19's impact on breast cancer outcomes, and AI in cancer diagnosis. These studies offer insights into overcoming drug resistance, enhancing immune responses, and improving outcomes for patients with difficult-to-treat cancers.
Researchers generated a comprehensive view of DNA methylation abnormalities in human MDS HSCs, uncovering a novel TET2-GFI1 axis that suppresses malignant transformation. The study identifies key hematopoietic regulators and provides a panoramic view of DNA methylation disruption in MDS.
A study published in Cell Reports reveals a two-phase model explaining the origin of childhood B-ALL, involving hyperdiploidy and subsequent malignant transformation. Hyperdiploidy causes chromosomal instability, delaying cell differentiation and allowing rare clones to persist without triggering leukaemia.
A new study found that maintaining a healthy weight from early adulthood is associated with lower risks of premature death from various diseases. Excess weight at 25 years old has lasting effects on mortality risk, independent of subsequent weight changes.
Researchers found that blocking clusterin, a molecule linked to stress and tumor growth, slows tumor growth signals and makes the cancer more responsive to cisplatin. The study's findings offer a possible strategy for treating cervical gastric-type adenocarcinoma, one of the most aggressive non-HPV associated cervical adenocarcinomas.
The American Society of Hematology and the International Society on Thrombosis and Haemostasis have released comprehensive guidelines for anticoagulant prophylaxis in non-cardiac pediatric patients at risk of venous thromboembolism. The guidelines outline best practices for preventing life-threatening complications in children.
The European Association of Nuclear Medicine (EANM) has joined the EMUC26 congress to promote nuclear medicine expertise in urological cancers. The event will bring together healthcare professionals from various disciplines to discuss current practices and emerging innovations.
Dr. Ulrich Steidl, MD, Ph.D., has been appointed as the director of the prestigious Montefiore Einstein Comprehensive Cancer Center and vice president of cancer medicine at Montefiore Einstein. With extensive experience in blood cancer and stem cell research, Dr. Steidl aims to advance innovative science that improves lives worldwide.
Researchers have identified a fundamental mechanism underlying Sanfilippo syndrome, a common form of childhood dementia. Chronic overactivity in the brain appears to be a key contributor to cognitive deterioration in children with the condition. The study's findings represent significant progress and may lead to personalized treatment ...
Researchers have created a detailed molecular map of the thromboxane A2 receptor, which could lead to the development of safer and more effective therapies targeting this clinically important signalling system. The study reveals an unusual activation switch and provides insights into how signalling molecules interact with the receptor.
Researchers at Umeå University have discovered a key protein that helps cancer cells survive treatment by blocking apoptosis. The study provides a deeper understanding of how proteins interact within the cell, which could lead to new cancer therapies targeting Bcl-2 and its protective function.
Researchers from St. Jude Children's Research Hospital discovered the gene-regulatory protein PHIP as a critical vulnerability in cancers driven by broad SWI/SNF inactivation. PHIP's loss disrupts cancer growth and cooperates with SWI/SNF to activate transcription, providing evidence for therapeutic development of PHIP-inhibiting drugs.
Advanced or metastatic cancers often go without tumor genomic testing, with those from low-income backgrounds facing longer wait times. JAMA Network Open highlights the need for targeted healthcare policies to bridge these gaps.
The NCCN Advocacy Academy connects oncology professionals with policymakers to drive evidence-based cancer policy. The program aims to cultivate policy leadership skills among emerging scientists and care providers.
Researchers discovered that neuronal nitric oxide synthase drives neuroblastoma through the mTOR signaling cascade. Treating cancer cells with a selective inhibitor called BA-101 collapsed tumor growth in mice with striking force, and silencing the nNOS gene also led to significant results.
A new study offers a powerful approach to personalized bladder cancer care using a non-invasive urine test. The test can detect minimal residual disease while accounting for mutations present in normal urothelium, allowing clinicians to distinguish between patients who benefit from additional therapy and those who don't.
Researchers studied cancer deaths in nearly 3,000 US counties from 1981-2019, finding urban and affluent counties experienced significant declines. However, rural areas often had lower rates of improvement, with some cities like New York City showing notable reductions in lung cancer mortality.
A new active agent enables photodynamic therapy to target cancer cells without relying on oxygen levels. The agent's interaction with intracellular iron triggers a rapid electron transfer process, generating highly reactive hydroxyl radicals that kill cancer cells.